Follow
avivit cahn
avivit cahn
Unknown affiliation
Verified email at hadassah.org.il
Title
Cited by
Cited by
Year
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
New England Journal of Medicine 380 (4), 347-357, 2019
56292019
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ...
The Lancet 393 (10166), 31-39, 2019
25572019
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal …
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ...
Circulation 139 (17), 2022-2031, 2019
6712019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ...
The lancet Diabetes & endocrinology 7 (8), 606-617, 2019
6512019
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ...
Circulation 139 (22), 2528-2536, 2019
6042019
Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 Trial
RHM Furtado, MP Bonaca, I Raz, TA Zelniker, O Mosenzon, A Cahn, ...
Circulation 139 (22), 2516-2527, 2019
3182019
Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial
O Mosenzon, G Leibowitz, DL Bhatt, A Cahn, B Hirshberg, C Wei, KA Im, ...
Diabetes care 40 (1), 69-76, 2017
2772017
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
American heart journal 200, 83-89, 2018
1732018
DECLARE‐TIMI 58: participants’ baseline characteristics
I Raz, O Mosenzon, MP Bonaca, A Cahn, ET Kato, MG Silverman, ...
Diabetes, Obesity and Metabolism 20 (5), 1102-1110, 2018
1512018
Clinical considerations for use of initial combination therapy in type 2 diabetes
A Cahn, WT Cefalu
Diabetes Care 39 (Supplement_2), S137-S145, 2016
1182016
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
A Cahn, R Miccoli, A Dardano, S Del Prato
The Lancet Diabetes & Endocrinology 3 (8), 638-652, 2015
1152015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
LA Leiter, H Teoh, E Braunwald, O Mosenzon, A Cahn, KMP Kumar, ...
Diabetes Care 38 (6), 1145-1153, 2015
1082015
Digital health technology and diabetes management: 数字化医疗技术与糖尿病管理
A Cahn, A Akirov, I Raz
Journal of diabetes 10 (1), 10-17, 2018
1062018
Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study
A Cahn, O Mosenzon, SD Wiviott, A Rozenberg, I Yanuv, EL Goodrich, ...
Diabetes care 43 (2), 468-475, 2020
932020
Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: real‐world data analysis
A Cahn, C Melzer‐Cohen, R Pollack, G Chodick, V Shalev
Diabetes, Obesity and Metabolism 21 (2), 340-348, 2019
812019
Prediction of progression from pre‐diabetes to diabetes: development and validation of a machine learning model
A Cahn, A Shoshan, T Sagiv, R Yesharim, R Goshen, V Shalev, I Raz
Diabetes/metabolism research and reviews 36 (2), e3252, 2020
732020
An update on DPP-4 inhibitors in the management of type 2 diabetes
A Cahn, S Cernea, I Raz
Expert opinion on emerging drugs 21 (4), 409-419, 2016
722016
Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial
O Mosenzon, C Wei, J Davidson, BM Scirica, I Yanuv, A Rozenberg, ...
Diabetes care 38 (11), 2142-2150, 2015
712015
Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial
BA Bergmark, DL Bhatt, DK McGuire, A Cahn, O Mosenzon, PG Steg, ...
Circulation 140 (12), 1004-1014, 2019
702019
The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58
O Mosenzon, SD Wiviott, HJL Heerspink, JP Dwyer, A Cahn, EL Goodrich, ...
Diabetes Care 44 (8), 1805-1815, 2021
672021
The system can't perform the operation now. Try again later.
Articles 1–20